# The Cooper Companies, Inc. (COO): Investor Outlook with a 9.41% Potential Upside

- Link: https://www.directorstalkinterviews.com/the-cooper-companies-inc-coo-investor-outlook-with-a-9-41-potential-upside/4121259842
- Published: 2026-08-10T10:16:50+01:00
- Author: Madison Wilson

For investors looking to explore opportunities in the healthcare sector, The Cooper
Companies, Inc. (NYSE: COO) presents a compelling case with a potential upside of
9.41%. With its diverse offerings in medical instruments and supplies, COO has managed
to carve a niche in the healthcare industry, particularly through its two main segments:
CooperVision and CooperSurgical.

CooperVision is renowned for its innovative contact lens solutions that cater to
visual impairments like astigmatism, presbyopia, and myopia. Meanwhile, CooperSurgical
focuses on women’s health, offering a suite of fertility products, medical devices,
and genomic services. This robust product portfolio not only addresses a wide array
of health needs but also positions COO favorably within the healthcare landscape.

As of the latest trading session, COO’s stock is priced at $74.23, slightly above
its 200-day moving average of $73.15. Although it has experienced a modest price
change of 0.91 (0.01%), it remains within its 52-week range of $58.98 to $84.32,
suggesting stable performance amidst market fluctuations.

The financial metrics paint an intriguing picture for prospective investors. While
the trailing P/E ratio is unavailable, the forward P/E stands at a reasonable 14.86,
indicating expectations of earnings growth. With a revenue growth rate of 7.90% 
and free cash flow exceeding $424 million, COO demonstrates sound financial health
and operational efficiency.

Investors should note the company’s modest return on equity of 2.85%, which highlights
a need for further scrutiny into operational strategies for enhancing shareholder
value. Despite the absence of a dividend yield, the company’s zero payout ratio 
suggests a reinvestment approach, potentially driving future growth.

Analyst sentiment towards COO is predominantly positive, with 10 buy ratings and
6 hold ratings. The consensus price target averages at $81.21, with a range from
$66.00 to $92.00. This translates to a potential upside of 9.41%, making it an attractive
proposition for growth-focused investors.

Technical indicators further support a positive short-term outlook. The Relative
Strength Index (RSI) sits at 42.45, indicating the stock is neither overbought nor
oversold. The Moving Average Convergence Divergence (MACD) of 1.30 above the signal
line of 1.19 suggests bullish momentum.

In the competitive sphere of medical instruments, COO’s strategic focus on eye care
and women’s health, coupled with its robust distribution network, positions it well
for continued success. As the company continues to innovate and expand its product
offerings, investors could find significant value in this healthcare stalwart. With
a solid foundation and promising growth prospects, The Cooper Companies, Inc. remains
a noteworthy consideration for those looking to diversify within the healthcare 
sector.

Share on:
